US equities |
NVDA $233.95 ▲+1.34% MU $1,074.89 ▼-2.05% TSLA $370.59 ▲+4.65% SPCX $158.96 ▲+7.35% SNDK $1,719.99 ▼-3.79% AMD $633.91 ▲+2.95% STX $848.99 ▼-10.21% INTC $119.33 ▼-0.56%
FinancialContent

Personalis, Inc. - Common Stock (NQ:PSNL)

16.28 +0.11 (+0.68%)
Delayed Quote Updated: 4:00 PM EDT, Oct 2, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Personalis, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9 10 11 Next >
News headline image
Halper Sadeh LLC is Investigating Whether CSR, FULC, WEAV, PSNL are Obtaining Fair Deals for their Shareholders
From Halper Sadeh LLC
Via GlobeNewswire
News headline image
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Centerspace (NYSE – CSR), Fulcrum Therapeutics, Inc. (Nasdaq – FULC), Weave Communications, Inc. (NYSE – WEAV), Personalis, Inc. (Nasdaq – PSNL)
From Brodsky & Smith LLC
Via GlobeNewswire
News headline image
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Personalis, Inc. (Nasdaq – PSNL), Werewolf Therapeutics, Inc. (Nasdaq – HOWL), Beazer Homes USA, Inc. (NYSE – BZH), MarketAxess Holdings Inc. (Nasdaq – MKTX)
From Brodsky & Smith LLC
Via GlobeNewswire
Personalis (NASDAQ:PSNL) Volume Surge Can't Mask Q1 Miss as Losses Widen ↗
Via Chartmill
News headline image
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Personalis, Inc. (Nasdaq – PSNL), Werewolf Therapeutics, Inc. (Nasdaq – HOWL), Beazer Homes USA, Inc. (NYSE – BZH), MarketAxess Holdings Inc. (Nasdaq – MKTX)
From Brodsky & Smith LLC
Via GlobeNewswire
News headline image
Halper Sadeh LLC is Investigating Whether UTZ, PSNL, DSGR are Obtaining Fair Deals for their Shareholders
From Halper Sadeh LLC
Via GlobeNewswire
News headline image
Personalis Reports Second Quarter Results and Recent Highlights
From Personalis, Inc.
Via Business Wire
News headline image
Halper Sadeh LLC is Investigating Whether UTZ, BLFS, FNWD, PSNL are Obtaining Fair Deals for their Shareholders
From Halper Sadeh LLC
Via GlobeNewswire
News headline image
Halper Sadeh LLC is Investigating Whether FNWD and PSNL are Obtaining Fair Deals for their Shareholders
From Halper Sadeh LLC
Via GlobeNewswire
News headline image
Halper Sadeh LLC is Investigating Whether LXP, FNWD, PSNL are Obtaining Fair Deals for their Shareholders
From Halper Sadeh LLC
Via GlobeNewswire
News headline image
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Luxfer Holdings PLC (NYSE – LXFR), Finward Bancorp (Nasdaq – FNWD), Personalis, Inc. (Nasdaq – PSNL), Distribution Solutions Group, Inc. (Nasdaq – DSGR)
From Brodsky & Smith LLC
Via GlobeNewswire
News headline image
Halper Sadeh LLC is Investigating Whether UTZ, PSNL, LXP are Obtaining Fair Deals for their Shareholders
From Halper Sadeh LLC
Via GlobeNewswire
News headline image
Personalis Investor Alert: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Personalis, Inc. - PSNL
From Kahn Swick & Foti, LLC
Via Business Wire
News headline image
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Personalis, Inc. (Nasdaq – PSNL), Distribution Solutions Group, Inc. (Nasdaq – DSGR), Cross Country Healthcare, Inc. (Nasdaq – CCRN), Nuvalent, Inc. (Nasdaq – NUVL)
From Brodsky & Smith LLC
Via GlobeNewswire
News headline image
PSNL Stock Alert: Halper Sadeh LLC is Investigating Whether Personalis, Inc. is Obtaining a Fair Price for Shareholders
From Halper Sadeh LLC
Via Business Wire
News headline image
Tempus to Acquire Personalis, More Tightly Integrating Molecular Residual Disease (MRD) into Its AI-Enabled Precision Oncology Platform
From Personalis, Inc.
Via Business Wire
News headline image
Personalis Accelerates Global Expansion with UKCA Marking for NeXT Personal®, Expanding MRD Access and Biopharma Support in Great Britain
From Personalis, Inc.
Via Business Wire
News headline image
Personalis Enables Global Biopharma Support with CE-IVD Marked Specimen Collection Kits
From Personalis, Inc.
Via Business Wire
News headline image
Personalis CEO Sells 100,000 Company Shares Worth $1.1 Million. What Does That Mean for Investors? ↗
This cancer genomics specialist, serving major biopharma and research clients, reported a notable insider sale in its latest SEC filing. 
Via The Motley Fool
Topics Regulatory Compliance
News headline image
Personalis Highlights Early Colorectal Cancer Recurrence Detection and Ultrasensitive MRD Performance Across a Broad Set of Tumor Types at ASCO 2026
From Personalis, Inc.
Via Business Wire
News headline image
Personalis to Highlight Breadth of NeXT Personal® Ultra-Sensitive ctDNA Data at ASCO 2026 Annual Meeting, Including Podium Presentation from TRACERx Consortium
From Personalis, Inc.
Via Business Wire
News headline image
Personalis Secures Fourth Medicare Coverage Decision for NeXT Personal®, Expanding Breast Cancer Coverage to Pre-Surgical Treatment Monitoring
From Personalis, Inc.
Via Business Wire
News headline image
Personalis to Participate in Upcoming Investor Events
From Personalis, Inc.
Via Business Wire
News headline image
Personalis Receives Medicare Coverage for NeXT Personal® for Immunotherapy Monitoring Across Late-stage Solid Tumors
From Personalis, Inc.
Via Business Wire
News headline image
Personalis Q1 Earnings Call Highlights ↗
Personalis (NASDAQ:PSNL) reported first-quarter 2026 revenue of $15.5 million as management said the company is prioritizing growth in its clinical minimal residual disease, or MRD, testing business... 
Via MarketBeat
Topics Earnings
News headline image
Personalis (PSNL) Q1 2026 Earnings Transcript ↗
Personalis (PSNL) Q1 2026 Earnings Transcript 
Via The Motley Fool
News headline image
Personalis Reports First Quarter Results and Recent Highlights
From Personalis, Inc.
Via Business Wire
News headline image
Personalis to Announce First Quarter 2026 Financial Results
From Personalis, Inc.
Via Business Wire
News headline image
Personalis Highlights Clinical Impact of Ultrasensitive ctDNA Monitoring and New Therapy Resistance Tracking at AACR 2026
From Personalis, Inc.
Via Business Wire
News headline image
Personalis and Collaborators to Highlight Ultrasensitive ctDNA Data and New Therapy Resistance Tracking Capabilities at AACR 2026
From Personalis, Inc.
Via Business Wire
< Previous 1 2 3 4 5 6 7 8 9 10 11 Next >